Ikaros Transcription Factor
"Ikaros Transcription Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transcription factor that plays a role as a key regulator of HEMATOPOIESIS. Aberrant Ikaros expression has been associated with LYMPHOBLASTIC LEUKEMIA.
| Descriptor ID |
D051740
|
| MeSH Number(s) |
D12.776.260.522.500 D12.776.930.375.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ikaros Transcription Factor".
Below are MeSH descriptors whose meaning is more specific than "Ikaros Transcription Factor".
This graph shows the total number of publications written about "Ikaros Transcription Factor" by people in this website by year, and whether "Ikaros Transcription Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ikaros Transcription Factor" by people in Profiles.
-
Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children-a novel health disparity. Leukemia. 2021 08; 35(8):2399-2402.
-
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020 09 24; 136(13):1520-1534.
-
The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020 Mar 22; 21(6).
-
Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity. Leukemia. 2019 11; 33(11):2720-2731.
-
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. Cancer Lett. 2019 01; 440-441:1-10.
-
Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. J Clin Invest. 2018 07 02; 128(7):3071-3087.
-
Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia. Adv Biol Regul. 2017 08; 65:16-25.
-
High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget. 2016 Aug 02; 7(31):49722-49732.
-
Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction. Oncotarget. 2016 Jul 19; 7(29):46014-46027.
-
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia. J Biol Chem. 2016 Feb 19; 291(8):4004-18.